Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 3Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Thymus Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Gastrointestinal Cancer 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × napabucasin × Clear all
NCT01325441 2023-11-15

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
565 enrolled 17 charts

Neoplasms, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡